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Abstract
INTRODUCTION—Few studies to date have explored patient and caregiver views on the clinical 
use of amyloid PET.
METHODS—A 7-item questionnaire assessing patient and caregiver views (510 total 
respondents) toward amyloid PET imaging was advertised broadly through alz.org/trialmatch.
RESULTS—We received 510 unique responses from 48 US states, two Canadian provinces, the 
Dominican Republic, and Greece. Both patients and caregivers indicated that they would want to 
receive amyloid imaging if offered the opportunity. Over 88% of respondents had a positive 
response (approximately 10% with neutral and 2% with negative responses) to whether amyloid 
PET should be offered routinely and be reimbursed. Such information was felt to be useful for 
long-term legal, financial and healthcare planning. Respondents identifying with early age 
cognitive decline (<65 years) were more likely to explore options for disability insurance (p = 
0.03). Responders from the Midwest were more likely to utilize information from amyloid 
imaging for legal planning (p = 0.02), disability insurance (p = 0.02), and life insurance (p = 0.04) 
than other US regions.
DISCUSSION—Patients and caregivers supported the use of amyloid PET imaging in clinical 
practice and felt that the information would provide significant benefits particularly in terms of 
future planning.
Keywords
Amyloid; positron emission tomography (PET); clinical use; Alzheimer’s disease (AD); patient; 
caregiver
1. Introduction
Alzheimer’s disease (AD) is the most common age-related neurodegenerative disease in the 
world. In the United States, approximately 5.5 million individuals have the disease and it is 
the sixth leading cause of death in the country. AD places a significant burden not only on 
persons affected by the disease, but also their families, with more than 15 million caregivers 
providing an estimated 18.2 billion hours of care in the year 2016.1 The burden faced by 
caregivers is not only due to time sacrificed and the challenges of a progressive disease, but 
also financial in nature and due to personal suffering.
Clinical diagnosis of AD is achieved by establishing the presence of progressive cognitive 
decline, while ruling out other causes of cognitive and functional impairment.2,3 The “gold 
standard” for definitive diagnosis of AD, however, is through discovering AD pathology 
during postmortem neuropathological examination using widely accepted criteria.4,5 Recent 
studies have assessed the accuracy of clinical diagnosis in comparison with neuropathology 
at autopsy, demonstrating sensitivity of 70.9%–87.3% and specificity of 44.3% –70.8%.6 
Thus, while clinical data is often used to deduce underlying AD pathology, clinical diagnosis 
is not robustly accurate.
Current studies suggest that AD initially begins in a presympomatic phase with abnormal 
processing of β-amyloid (Aβ) peptide, leading to accumulation of amyloid plaques in the 
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brain. This is followed by neuronal injury and degeneration, a tau-mediated process, 
accompanied by synaptic dysfunction, leading to eventual cognitive symptoms and the 
syndrome of dementia.7 This model for AD pathophysiology has led to the consensus that 
biomarker evidence for brain amyloid deposition would enhance specificity in the diagnosis 
of AD.2
In recent years, there have been many biomarker developments to assist in the diagnosis of 
AD. Of these, some of the most significant are positron emission tomography (PET) 
imaging ligands with strong affinity for Aβ plaques, allowing for in vivo visualization of AD 
pathology. Three amyloid PET ligands, F18-Florbetapir, F18-Florbetaben, and F18-
Flutemetamol, have recently achieved U.S. Food and Drug Administration (FDA) approval 
in the United States.8–14 Diagnostic performance for these compounds was presented in the 
results of phase 3 trials demonstrating a median sensitivity of 92% and specificity of 95% 
for F18-Florbetapir 10, a median sensitivity of 88% and specificity of 92% for F18-
Florbetaben 9, and a median sensitivity of 98% and specificity of 85% for F18-Flutemetamol.
14
 A recent meta-analysis of F18-Florbetapir and F18-Florbetaben showed similar 
sensitivities and slightly lower specificities compared to those published in the phase 3 trials.
15
 It is important to reiterate that the sensitivity and specificity values from the phase 3 trials 
are for the detection of amyloid plaques compared to autopsy tissues – not for the diagnosis 
of AD. Two other meta-analyses recently determined that amyloid imaging has 95% 
sensitivity and 57% specificity for predicting conversion from mild cognitive impairment to 
AD16 and suggested that amyloid PET might be particularly useful in the diagnostic work-
up of early-onset dementia.17 While these results suggest benefit in specific clinical 
circumstances, amyloid PET is not currently part of routine clinical care in the United States 
and recommendations for which patient populations would benefit the most from amyloid 
PET are being developed. Appropriate use criteria have been proposed for persons with 
persistent or unexplained mild cognitive impairment, for those with atypical AD 
presentation or with suspected mixed etiology, and for those with progressive dementia with 
atypical early age of onset.18
In 2013, the United States Centers for Medicare & Medicaid Services (CMS) released a 
statement that there is insufficient evidence that amyloid PET imaging improves patient 
outcomes and declined to provide reimbursement.19 However, CMS did opt to provide 
coverage with evidence development (CED), meaning that the procedure is only covered in 
the context of an approved clinical study.19 This mechanism allows investigation into the 
utility of amyloid PET for diagnostically challenging clinical scenarios and to assist with 
clinical trials for treatment and prevention of AD. To date, several small single-center studies 
have suggested that amyloid imaging can affect diagnostic and treatment decisions.20–26 A 
large, multi-center CMS funded study to examine the diagnostic and therapeutic benefits of 
amyloid imaging, its cost effectiveness, and its impact on patient outcomes is presently 
ongoing (http://www.ideas-study.org/).
While many studies have evaluated the diagnostic or prognostic implications associated with 
amyloid PET, few have explored its effects on the patient or caregiver. Not only may 
amyloid imaging help clinicians with their diagnosis and management, but it may also affect 
patient and caregiver decisions related to lifestyle and financial planning, long-term care, 
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and employment.18 Diagnostic uncertainty can lead to anxiety and depression among 
patients, which have been associated with negative quality of life outcomes for both patients 
and caregivers.27 Receiving a diagnosis of AD and disease education has been shown to 
decrease such anxiety in patients28 and to have positive effects on caregiver burden and 
depression.21,29 A few recent studies have qualitatively explored patient and caregiver views 
toward AD and mild cognitive impairment.28,30–32 So far, these studies have been small and 
none have directly explored patient and caregiver views toward amyloid PET imaging. A 
single small study involving 28 patients and 23 caregivers, which explored the impact of 
amyloid PET on patients and caregivers, demonstrated that caregivers appreciated the results 
of imaging and had an impact on their future plans.21 Here, we report the largest sample 
analysis of patient and caregiver views toward amyloid PET imaging and its potential use in 
routine clinical practice.
2. Methods
2.1 Study Design
Our dataset consisted of 510 participants who answered 7 questions provided through an 
online questionnaire designed to obtain the thoughts and feelings of patients and caregivers. 
The questionnaire can be seen in Figure 1. The vast majority of these participants (N=487) 
were invited through the Alzheimer’s Association TrialMatch mailing list, while others were 
directed to the questionnaire by the Indiana Alzheimer Disease Center website (N=8), the 
2015 FTD Caregiver Conference (N=5), a family member (N=3), or an unknown source 
(N=7). Participants were informed that they are eligible for the study only if they or the 
person they provide care for had memory loss or dementia.
All participants were given a brief introduction about amyloid PET with an explanation that 
this type of imaging is currently FDA approved, yet does not have insurance coverage, and is 
not part of routine clinical care (see Figure 1). Participants were given a one page 
questionnaire asking open-ended questions of their feelings about the lack of amyloid PET 
imaging in routine clinical diagnosis, whether they believed additional research on amyloid 
PET would be beneficial, and whether they would choose to pursue amyloid PET if offered 
the opportunity (Figure 1). Additionally, participants were able to report whether they 
thought receiving a diagnosis early on through amyloid imaging would be beneficial for 
legal planning, financial advice, disability insurance, life insurance, long-term care 
insurance, communicating with family members, learning more about their diagnosis, or 
“other” scenarios. Finally, participants were asked to report how old they or the person they 
care for were when cognitive decline began and to provide their current city and state. 
Additional demographic information was not acquired in order to maintain confidentiality 
and anonymity (see Figure 1).
2.2 Data Analyses
Answers to the questionnaire were recorded verbatim. We reviewed each participant’s 
responses fully, then categorized the data for analyses. The question “How do you feel about 
the lack of amyloid PET imaging for diagnosis?” elicited a variety of responses, which were 
categorized as follows: 1) positive responses - responses stating amyloid imaging would be 
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beneficial in patient care such as “If the PET scan is an effective tool…, then it should be 
covered by insurance and available to those effected by memory loss and other symptoms.”; 
2) emotionally charged positive responses – positive responses containing the words 
“alarming”, “appalling”, “angry”, “cheated”, “criminal” or “it's a crime”, “disappointing”, 
“discouraged”, “disheartened”, “feel bad”, “feel sorry”, “frustrated”, “hate”, “indignant”, 
“not happy”, “outraged”, “petrified”, “pitiful”, “sad”, “scary”, “terrible”, “travesty”, 
“unfortunate”, “upset”; 3) neutral responses - responses that were neither positive nor 
negative as in “I don't know enough about it to have an opinion.”; and 4) negative responses 
- responses that were not supportive of this type of imaging such as “I understand why 
insurance doesn't feel it would be helpful”. Questions about participants’ beliefs on whether 
further research into amyloid imaging would be beneficial, whether participants would 
choose to pursue amyloid imaging if offered the opportunity, and whether receiving an early 
diagnosis would be beneficial for the various scenarios were not further categorized.
While we did not specifically ask whether the respondent was a patient or a caregiver, 63.3% 
of the respondents provided that information in their answers (i.e., “I was 54 when my 
doctor broke the news…” vs. “my mother was diagnosed with Alzheimer’s…”). This 
allowed for the dichotomization of patient vs. caregiver status in 323 of our 510 cases.
Responses were also divided by self-reported age of onset of cognitive decline as early-onset 
(less than age 65) or late-onset (65 and older).
Geographically we divided responses as coming from urban vs. rural area based on the U.S. 
Department of Health and Human Services, 2013 National Center for Health Statistics 
Urban-Rural Classification Scheme33,34 and by U.S. regions (i.e., Northeast, Midwest, 
South, and West) based on the U.S. Census Bureau region classification.35
2.3 Statistical Methods
We used Pearson’s chi-squared tests to compare response data between 1) patients and 
caregivers, 2) early onset and late onset cases, 3) urban and rural residents, and 4) US 
geographic regions. When analyzing data by U.S. regions, in order to determine which 
particular regions were driving the statistical significance in various scenarios, standardized 
Pearson residuals were determined.36 All statistical analyses were done with IBM SPSS 
Statistics 24. Analyses of the study responses among the different groups were performed on 
the data that could be assigned to the specific divisions, leaving unknown data out of the 
analysis.
3. Results
3.1 Sample Characteristics
Our dataset consisted of 510 total participants. The responses were categorized as 87 
(17.1%) patients and 236 (46.2%) caregivers. We were unable to assign 187 (36.7%) of the 
responses to a participant category due to missing information. Based on age when cognitive 
decline began, 215 (42.2%) were categorized as early-onset and 270 (52.9%) were 
categorized as late-onset. Twenty-five (4.9%) were unassigned as these participants did not 
provide an answer for the age on onset. Geographically, 446 (87.4%) of responses were from 
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urban areas while 59 (11.6%) of responses were from rural areas. Divided by U.S. region, 
the responses were categorized as 83 (16.2%) Northeast, 114 (22.4%) Midwest, 182 (35.7%) 
South, and 119 (23.3%) West. Five (1.0%) participants did not provide their current city and 
state, and so these responses were not assigned to the urban vs. rural division of responses. 
An additional seven participants were from locations in Canada, Greece, and the Dominican 
Republic and so a total of 12 (2.4%) of responses were unassigned when dividing responses 
by U.S. regions. Forty-eight U.S. states (not included: Rhode Island and Wyoming), two 
Canadian provinces (British Columbia and Ontario), and cities in the Dominican Republic 
(Santiago) and Greece (Athens) were represented among the responses provided.
Additional analysis of the data showed that there were significantly more patients vs. 
caregivers among early-onset (44.2% patients vs. 55.8% caregivers) than late-onset cognitive 
decline (12.6% patients vs. 87.4% caregivers), p <0.0001. There were no significant 
differences between the number of patients vs. caregivers or early-onset vs. late-onset 
participants when analyzed by urban vs. rural or U.S. regional distributions.
3.2 Questionnaire Results
Table 1 details the overall responses obtained from participants (N=510) who answered the 
questionnaire. Of the responses regarding the lack of amyloid PET imaging in routine 
clinical diagnosis, 325 (63.7%) of the responses were categorized as positive (in favor of 
amyloid imaging), 125 (24.5%) as positive and emotionally charged, 51 (10.0%) as neutral, 
and 9 (1.8%) as negative.
When participants were asked whether they believed additional research on amyloid PET 
would be beneficial, 507 (99.4%) responded yes. A large number of responders, 508 
(99.6%), also stated they would choose to pursue amyloid PET if offered the opportunity. 
The majority cited the benefit of having definitive diagnosis as the reason for pursuing 
amyloid imaging. Interestingly, all 9 responders who felt the absence of insurance coverage 
for amyloid PET is justifiable stated that they would pursue an amyloid PET scan if 
recommended by their doctor.
Early diagnosis obtained through amyloid imaging was thought to be beneficial for legal 
planning by 446 (87.5%), for financial advice by 392 (76.9%), for disability insurance by 
306 (60.0%), for life insurance by 250 (49.0%), for long-term care insurance by 345 
(67.6%), for communicating with family members by 467 (91.6%), for learning more about 
their diagnosis by 474 (92.9%), and for “other” scenarios by 123 (24.1%) participants. 76 of 
the 123 “other” responses simply restated one or more of the options that were already 
listed. 46 were new items. Another 12 subjects made comments in this field that listed other 
benefits without checking the box “other”. The additional benefits among these 58 new 
responses consisted of eligibility for participation in clinical trials (26%), starting early 
treatment (21%), focusing on “enjoying life” (17%), adjusting/adapting to diagnosis (12%), 
participation in support groups (7%), decreased anxiety and stress (5%), engaging in 
spiritual pursuits (3%), increasing one’s awareness of his/her cognitive problems (3%), 
participation in brain donation program (2%), modifying home to meet one’s needs (2%) 
and aggressively addressing any other health issues (2%). Additional 16 participants voiced 
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concerns with amyloid PET affecting their ability to sign up for long-term care and life 
insurance.
Table 2–5 describe the distribution of responses in our subgroup analyses. No significant 
differences were present among patients vs. caregivers, early-onset vs. late-onset cognitive 
decline, urban vs. rural locations, or among U.S. regions regarding their reaction to the 
unavailability of amyloid imaging in clinic (Table 2), their perceived need for additional 
research on amyloid PET (Table 3) and their willingness to subject themselves to amyloid 
imaging if recommended by their doctor (Table 4). There were no significant differences 
between patients vs. caregivers or urban vs. rural subgroups in terms of their intent to pursue 
more information about the disease, legal and financial planning, to explore their options for 
disability, long-term care and life insurance, and to communicate their diagnosis and 
prognosis with their families (Table 5). Those with early-onset cognitive decline were more 
likely to utilize information from amyloid imaging to explore their options for disability 
insurance than those with late-onset cognitive decline (66.0% early-onset vs. 54.8% late-
onset, p = 0.03), however both groups did not differ in terms of the other long-term planning 
scenarios (Table 5).
Among the data divided by U.S. region, significant differences were found among 
participants in utilizing information from amyloid imaging for legal planning (88.0% 
Northeast vs. 93.0% Midwest vs. 86.3% South vs. 84.0% West, p=0.02), for disability 
insurance (67.5% Northeast vs. 67.5% Midwest vs. 55.5% South vs. 54.6% West, p=0.02), 
and for life insurance (48.2% Northeast vs. 60.5% Midwest vs. 46.2% South vs. 42.9% 
West, p=0.04) (Table 5). In all of these scenarios, respondents from the Midwest showed a 
significant positive trend indicating a greater likelihood for pursuing these actions in 
comparison to the other three regions (legal planning – 93.0% of Midwest, std Pearson 
residual = 2.8; disability insurance – 67.5% of Midwest, std Pearson residual = 2.0; life 
insurance – 60.5% of Midwest, std Pearson residual = 2.8). No differences were found 
between U.S. regions in terms of the other long-term planning scenarios (Table 5).
4. Discussion
Our data suggest that most patients and caregivers believe amyloid imaging would be 
beneficial in patient care. The majority of participants had positive responses for the use of 
amyloid imaging in clinical practice, with many reflecting strong emotional feelings such as 
frustration, anger, and disappointment for the lack of amyloid imaging in routine clinical 
practice in the absence of insurance coverage. Few participants had neutral feelings about 
the lack of imaging often stating they needed more information to give a thoughtful answer. 
Even fewer participants were comfortable with the current unavailability of amyloid PET in 
the clinic, frequently explaining that without any disease-modifying therapies available for 
AD, amyloid imaging may have no therapeutic benefit.
Nearly all participants believed additional research into amyloid PET imaging would be 
beneficial and would pursue amyloid imaging if recommended by their doctor, with most 
responders citing the benefit of having a definitive diagnosis as their reason for pursuing the 
test. Surprisingly, of those participants who had neutral feelings about the lack of amyloid 
Mustafa et al. Page 7
Alzheimer Dis Assoc Disord. Author manuscript; available in PMC 2019 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
imaging (N=51, 10.0%), 49/51 (96.1%) stated they would pursue amyloid imaging if given 
the opportunity. The two subjects who said that at this time they will opt out from amyloid 
imaging cited lack of treatment as the reason behind refusing to subject themselves to this 
diagnostic imaging modality. All participants who were comfortable with the lack of 
coverage of amyloid PET at this time (N=9, 1.8%) nonetheless stated they would pursue 
amyloid imaging if offered.
Receiving amyloid PET results was believed to be most beneficial for learning more about 
the diagnosis, communicating with family, and legal planning followed by financial 
planning, purchasing long-term care, disability, and life insurance, and other reasons such as 
finding support groups, establishing home care, and participating in clinical trials. 
Interestingly, no significant differences were found in responses from patients vs. caregivers 
or from urban vs. rural responders. However, significantly more responders with early-onset 
cognitive decline were likely to use information from amyloid imaging to explore options 
for disability insurance than responders with late-onset cognitive decline. The likely 
explanation for this is that younger patients and their caregivers are more likely to be still 
involved with their careers or are not yet eligible for Medicare or as financially established 
as some of their older counterparts.
In terms of U.S. regional differences, we found that significantly more responders from the 
Midwest would utilize information from amyloid imaging for legal planning, disability and 
life insurance than the other regions, particularly the South and the West. The U.S. Census 
Bureau reports that the rate of educational attainment (High School or greater education) is 
highest in the Midwest, followed by the Northeast, West, and then the South.37 In regards to 
health insurance coverage, the U.S. Census Bureau also reports that the uninsured rate is 
lowest in the Northeast and Midwest, followed by the West, and then the South.38 It is 
possible that these trends serve as an explanation for why participants from the Midwest 
were more likely to use information from amyloid imaging for the various life planning 
scenarios compared with other regions.
We observed significantly more patients vs. caregivers among those with early-onset than 
among those with late-onset cognitive decline. There could be several reasons for this 
imbalance. It is possible that persons with early-onset cognitive decline have greater 
emotional connection with their disease given the timing of onset and are thus more inclined 
to participate in studies such as ours. Among those with late-onset cognitive decline, perhaps 
the caregivers, heavily burdened by financial and time-intensive sacrifices, are more 
emotionally involved and thus more inclined to participate. It is also possible that the older 
patients are simply less inclined to use a computer and be digitally subscribed to TrialMatch 
compared with their younger counterparts. Regardless, it is important to note that were no 
significant differences in the responses between patients and caregivers from the early-onset 
vs. the late-onset groups.
Several strengths and limitations of our study are worth discussion. Patients and caregivers 
were invited to participate only if they or the ones they provide care for were affected by 
memory loss or dementia. No further participation restrictions were used and no objective 
verification of a diagnosis of cognitive decline was made. Thus, responses from participants 
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not affected by dementia and more specifically AD may have been included and could have 
impacted our results. In our questionnaire, the only demographic questions asked were 
related to current location and age of onset for cognitive decline. While we limited 
demographic information to lessen the burden of taking part in the study and to also 
maintain confidentiality and anonymity, additional participants’ characteristics such as age, 
sex, race, education level, socioeconomic status and patient/caregiver status may have been 
helpful to further understand participants’ views on amyloid imaging. We do not know how 
the omission of these questions may have affected trends among different groups. Additional 
limitations may include the pre-survey information and phrasing of the questions, which 
may bias towards a positive response to amyloid imaging; and response bias from those who 
are more in favor of the technique being more likely to respond to the survey questions.
AD has a significant impact among both patients and caregivers. Clinical diagnosis of AD 
shows moderate accuracy, even among experts in the field. Amyloid PET imaging has 
demonstrated significant promise for improving diagnostic accuracy. While the value of 
amyloid PET toward improving patient outcomes remains debated, ongoing research studies 
will likely influence payers’ coverage decisions related to this imaging modality as well as 
its incorporation into clinical care in the United States. It will be important to not only 
consider the impact of amyloid PET on diagnosis, treatment, and patient outcomes, but also 
on how it harmonizes with the values of patients and caregivers themselves. Our data 
suggest that patients and caregivers feel that amyloid PET imaging would be beneficial in 
clinical practice and that additional research into amyloid imaging would be useful. They 
would also tend to pursue amyloid imaging if presented the opportunity and believe that 
diagnosis assisted by such imaging would be useful for various long-term planning scenarios 
ranging from legal planning to participation in clinical trials. Factors such as geography, 
education, and health insurance coverage may also play a role with decisions for future 
planning. Further studies will be needed to thoroughly assess the value of amyloid imaging 
in the lives of patients and caregivers and to understand its impact from their perspective.
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Figure 1. 
Amyloid PET questionnaire
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Table 1
Response frequencies in the pooled sample (% represents positive responses unless otherwise noted)
N (%)
TOTAL RESPONSES 510 (100)
REACTION TO THE UNAVAILABILITY OF AMYLOID IMAGING IN THE CLINIC:
   POSITIVE (IN FAVOR OF AMYLOID IMAGING) 325 (63.7)
   POSITIVE (EMOTIONALLY CHARGED) 125 (24.5)
   NEUTRAL 51 (10.0)
   NEGATIVE (NOT IN FAVOR OF AMYLOID IMAGING) 9 (1.8)
ADDITIONAL RESEARCH WILL BE BENEFICIAL 507 (99.4)
WILLINGNESS TO SUBJECT ONESELF TO AMYLOID IMAGING IF OFFERED 508 (99.6)
BENEFITS OF EARLY DEFINITIVE DIAGNOSIS:  
   LEGAL PLANNING 446 (87.5)
   FINANCIAL ADVICE 392 (76.9)
   DISABILITY INSURANCE 306 (60.0)
   LIFE INSURANCE 250 (49.0)
   LONG-TERM CARE INSURANCE 345 (67.6)
   COMMUNICATING WITH FAMILY 467 (91.6)
   LEARNING MORE ABOUT DIAGNOSIS 474 (92.9)
   OTHER 123 (24.1)
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